Huisheng oral liquid combined with TACE for treatment of primary hepatic carcinoma: Meta-analysis
10.13929/j.1672-8475.201903023
- VernacularTitle: Meta分析回生口服液联合TACE治疗原发性肝癌疗效
- Author:
Jianjian CHEN
1
Author Information
1. Department of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University
- Publication Type:Journal Article
- Keywords:
Embolization, therapeutic;
Huisheng oral liquid;
Liver neoplasms;
Meta-analysis
- From:
Chinese Journal of Interventional Imaging and Therapy
2019;16(9):545-549
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To evaluate the efficacy of Huisheng oral liquid combined with TACE for treatment of primary hepatic carcinoma (PHC) with meta-analysis. Methods: Literature on the treatment of PHC with Huisheng oral liquid combined with TACE in CNKI, Wanfang, VIP, Pubmed, EMbase and Cochrane Library were searched from the establishment of database to October 2018. Meta-analysis of the included articles was performed using Stata 15.0 software. Results: Eight literature were enrolled, including 535 patients with intermediate stage PHC, of which 270 patients were treated with Huisheng oral liquid combined with TACE (study group) and 265 patients were treated with TACE alone (control group). The objective response ratio (risk ratio [RR]=1.39, 95%CI [1.19, 1.63], P<0.01), disease control ratio (RR=1.13, 95%CI [1.04, 1.23], P<0.01) and improvement of Karnofsky performance status score (RR=1.64, 95%CI [1.36, 1.98], P<0.01) were all improved in study group. Conclusion: Huisheng oral liquid combined with TACE is effective and safe for treatment of PHC.
